APUS
Apimeds Pharmaceuticals Us
$6.29
+$0.64 (+11.33%)Jul 27, 2026
Key metrics
The numbers that frame APUS today
- Market cap
- $9.49M
- P/E (TTM)
- -0.2
- EV / FCF
- -0.9
- ROIC
- -56.1%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $5.44
- 52wk High
- $59.70
Growth
Revenue and earnings trend for APUS
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about APUS
Is Apimeds Pharmaceuticals Us a good buy?
No. Apimeds Pharmaceuticals Us has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Apimeds Pharmaceuticals Us is selling at a very high price.
What is the market capitalization of APUS?
Apimeds Pharmaceuticals Us's market capitalization is $9.49M.
What is the P/E ratio for APUS stock?
Apimeds Pharmaceuticals Us's current P/E ratio is -0.2.
What is the 52-week high for APUS stock?
The 52-week high for Apimeds Pharmaceuticals Us is $59.70. The current close of $6.29 is 89.5% below that high.
What is the 52-week low for APUS stock?
The 52-week low for Apimeds Pharmaceuticals Us is $5.44. The current close of $6.29 is 15.6% above that low.
Does APUS stock pay dividends?
Apimeds Pharmaceuticals Us does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for APUS?
Apimeds Pharmaceuticals Us's Debt / Equity ratio is 0.08.